September 14, 2020 -- Molecular diagnostics company LuminUltra has submitted its GeneCount COVID-19 reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay for emergency use authorization with the U.S. Food and Drug Administration (FDA). The Canada-based company also submitted an interim order with Health Canada.
With approvals from the U.S. and Canadian agencies, LuminUltra will be able to provide its complete COVID-19 testing solution for facilities in North America.
The COVID-19 RT-qPCR assay is a part of the company's end-to-end testing solution for the novel coronavirus that can provide test results in under two hours, according to LuminUltra. The company's other COVID-19 offerings include sample collection kits, isolation reagents, and qPCR devices.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current